小细胞肺癌的影像学:当前与新兴应用的更新综述
本文综述小细胞肺癌影像学应用进展,指出CT、MRI和氟18脱氧葡萄糖PET/CT仍是诊断、分期和疗效评估的基础,代谢肿瘤体积和总病灶糖酵解等半定量PET/CT指标较最大标准化摄取值预后价值更强,影像组学、放射基因组学和机器学习等新兴方法可能进一步实现无创肿瘤表征和结局预测,分子影像如靶向δ样配体3和生长抑素受体的免疫PET代表向生物标志物引导的个体化治疗迈出的关键步骤。
要点
- CT、MRI和氟18脱氧葡萄糖PET/CT是小细胞肺癌诊断、分期和疗效评估的基础影像方法。
- 代谢肿瘤体积和总病灶糖酵解等半定量PET/CT指标与小细胞肺癌肿瘤增殖相关,预后价值强于最大标准化摄取值。
- 靶向δ样配体3和生长抑素受体的免疫PET等分子影像进展,代表向生物标志物引导的个体化治疗迈出的关键步骤。
核心结论
- 整合结构、功能和分子影像与生物学见解,预期将塑造这种高度侵袭性恶性肿瘤精准肿瘤学的下一阶段。
研究设计与样本
- 综述,总结小细胞肺癌影像学不断演变的范围,并强调支持个体化医疗的新兴方法。
诊断标准与关键数值
- 代谢肿瘤体积和总病灶糖酵解等半定量、基于体积的PET/CT指标与小细胞肺癌肿瘤增殖相关,预后价值强于最大标准化摄取值。
临床应用与阅片要点
- 常规影像CT、MRI和氟18脱氧葡萄糖PET/CT仍用于小细胞肺癌的诊断、分期和治疗反应评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Small cell lung cancer (SCLC) is an aggressive pulmonary neuroendocrine carcinoma characterized by rapid progression and early metastasis. Despite recent therapeutic advances, including immune checkpoint inhibitors and emerging targeted agents, survival outcomes remain poor. Recent molecular insights have identified four transcription factor-driven subtypes-SCLC-A, SCLC-N, SCLC-P, and the inflamed subtype SCLC-I-providing a framework for precision and immunotherapy-based strategies. This review summarizes the evolving scope of imaging in SCLC and highlights emerging approaches that support personalized medicine. Conventional imaging with CT, MRI, and fluorine 18 fluorodeoxyglucose PET/CT remains essential for diagnosis, staging, and treatment response assessment. Semiquantitative, volume-based PET/CT metrics, such as metabolic tumor volume and total lesion glycolysis, correlate with tumor proliferation and provide stronger prognostic value than maximum standardized uptake value. Emerging imaging approaches, including radiomics, radiogenomics, and machine learning, may further enable noninvasive tumor characterization and outcome prediction. Recent advances in molecular imaging, including delta-like ligand 3- and somatostatin receptor-targeted immune-PET, represent key steps toward biomarker-guided and personalized therapy. Together, integration of structural, functional, and molecular imaging with biologic insights is expected to shape the next phase of precision oncology in this highly aggressive malignancy. Keywords: Lung, Imaging Modality, PET, MRI, Molecular Imaging, Oncology, Neoplasms-Primary, CT, MR Imaging, Diagnosis, PET/CT, Small Cell Lung Cancer, Radiogenomics, Machine Learning, Radiolabeled Tracer, Personalized Medicine Supplemental material is available for this article. © RSNA, 2026.
引用
- Cha MJ, Choi H, Nam B, et al. Imaging of Small Cell Lung Cancer: An Updated Overview of Current and Emerging Applications. Radiol Imaging Cancer. 2026. PMID: 42065647. doi:10.1148/rycan.250644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。